Clinical trial
Evaluation of Low Dose Infliximab in Ankylosing Spondylitis (Study P04352)
NCT00202865 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00202865 |
|---|---|
| Title | Evaluation of Low Dose Infliximab in Ankylosing Spondylitis (Study P04352) |
| Official title | CANaDian Evaluation of Low DosE Infliximab in Ankylosing Spondylitis |
| Acronym | CANDLE |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Spondylitis, Ankylosing |
| Intervention type | Biological |
| Interventions | infliximab, Placebo |
| Enrollment | 76 |
| Start date | May 1, 2005 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Sep 20, 2005 |
| Last update posted | Mar 24, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: